文献速递神经肌肉病神经免疫

自体RNA嵌合抗原受体T细胞疗法治疗重症肌无力的安全性与临床活性(MG-001):一项前瞻性、多中心、开放标签、非随机1b/2a期研究

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
PubMed 文献 · Lancet Neurol · 2023-01-01

MG-001是一项前瞻性、多中心、开放标签、非随机1b/2a期研究,评估自体抗B细胞成熟抗原(BCMA)RNA嵌合抗原受体T细胞(rCAR-T)疗法Descartes-08治疗全身型重症肌无力(MG-ADL评分≥6)的安全性和临床活性。14例受试者入组(1b期3例,2a期11例),未使用淋巴细胞清除化疗。未观察到剂量限制性毒性、细胞因子释放综合征或神经毒性;从基线至第12周,MG-ADL评分平均改善-6(95%CI -9至-3),定量重症肌无力评分-7(-11至-3),重症肌无力综合评分-14(-19至-9),重症肌无力生活质量15项修订版评分-9(-15至-3)。Descartes-08似乎安全且耐受性良好,rCAR-T疗法值得进一步研究。

要点

  • Descartes-08为自体抗BCMA RNA CAR-T疗法,治疗全身型重症肌无力未使用淋巴细胞清除化疗。
  • 未观察到剂量限制性毒性、细胞因子释放综合征或神经毒性。
  • 第12周MG-ADL评分较基线平均改善-6(95%CI -9至-3),随访至9个月。

核心结论

  • 在这项首次将rCAR-T疗法用于自身免疫病的研究中,Descartes-08似乎安全且耐受性良好。
  • Descartes-08输注后,在长达9个月的随访中,重症肌无力严重程度量表出现有临床意义的下降。
  • rCAR-T疗法值得进一步研究,作为重症肌无力和其他自身免疫病患者的潜在新治疗方法。

研究设计与样本

  • MG-001是一项前瞻性、多中心、开放标签、1b/2a期研究,评估Descartes-08(自体抗BCMA rCAR-T疗法)治疗成人(年龄≥18岁)全身型重症肌无力且MG-ADL评分≥6的患者。
  • 研究在美国8个中心(学术医学中心或社区神经科诊所)进行,未使用淋巴细胞清除化疗。
  • 第1部分(1b期):MGFA疾病分级III-IV级的全身型重症肌无力受试者接受三个递增剂量的Descartes-08以确定最大耐受剂量。
  • 第2部分(2a期):MGFA疾病分级II-IV级的全身型重症肌无力受试者在门诊接受六个最大耐受剂量的Descartes-08。
  • 主要目标为确定Descartes-08的安全性和耐受性;次要目标为评估接受Descartes-08受试者的重症肌无力疾病严重程度和生物标志物。

主要发现

  • 2020年1月7日至2022年8月3日期间招募16例个体进行筛选,14例入组(第1部分n=3,第2部分n=11);10例女性,4例男性。
  • 2例因基线MG-ADL评分低(n=1)或缺乏全身型疾病(n=1)不符合条件;第2部分中位随访5个月(范围3-9个月)。
  • 未观察到剂量限制性毒性、细胞因子释放综合征或神经毒性;常见不良事件为头痛(14例中6例)、恶心(14例中5例)、呕吐(14例中3例)和发热(14例中4例),均在输注后24小时内缓解。
  • 发热与细胞因子释放综合征标志物(IL-6、IL-2和TNF)升高无关。
  • 从基线至第12周的平均改善:MG-ADL评分-6(95%CI -9至-3),定量重症肌无力评分-7(-11至-3),重症肌无力综合评分-14(-19至-9),重症肌无力生活质量15项修订版评分-9(-15至-3)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • rCAR-T疗法值得进一步研究,作为重症肌无力和其他自身免疫病患者的潜在新治疗方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chimeric antigen receptor (CAR) T cells are highly effective in treating haematological malignancies, but associated toxicities and the need for lymphodepletion limit their use in people with autoimmune disease. To explore the use of CAR T cells for the treatment of people with autoimmune disease, and to improve their safety, we engineered them with RNA (rCAR-T)-rather than the conventional DNA approach-to target B-cell maturation antigen (BCMA) expressed on plasma cells. To test the suitability of our approach, we used rCAR-T to treat individuals with myasthenia gravis, a prototypical autoantibody disease mediated partly by pathogenic plasma cells. METHODS: MG-001 was a prospective, multicentre, open-label, phase 1b/2a study of Descartes-08, an autologous anti-BCMA rCAR-T therapy, in adults (ie, aged ≥18 years) with generalised myasthenia gravis and a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of 6 or higher. The study was done at eight sites (ie, academic medical centres or community neurology clinics) in the USA. Lymphodepletion chemotherapy was not used. In part 1 (phase 1b), participants with Myasthenia Gravis Foundation of America (MGFA) disease class III-IV generalised myasthenia gravis received three ascending doses of Descartes-08 to determine a maximum tolerated dose. In part 2 (phase 2a), participants with generalised myasthenia gravis with MGFA disease class II-IV received six doses at the maximum tolerated dose in an outpatient setting. The primary objective was to establish safety and tolerability of Descartes-08; secondary objectives were to assess myasthenia gravis disease severity and biomarkers in participants who received Descartes-08. This trial is registered with clinicaltrials.gov, NCT04146051. FINDINGS: We recruited 16 individuals for screening between Jan 7, 2020 and Aug 3, 2022. 14 participants were enrolled (n=3 in part 1, n=11 in part 2). Ten participants were women and four were men. Two individuals did not qualify due to low baseline MG-ADL score (n=1) or lack of generalised disease (n=1). Median follow-up in part 2 was 5 months (range 3-9 months). There was no dose-limiting toxicity, cytokine release syndrome, or neurotoxicity. Common adverse events were headache (six of 14 participants), nausea (five of 14), vomiting (three of 14), and fever (four of 14), which resolved within 24 h of infusion. Fevers were not associated with increased markers of cytokine release syndrome (IL-6, IL-2, and TNF). Mean improvements from baseline to week 12 were -6 (95% CI -9 to -3) for MG-ADL score, -7 (-11 to -3) for Quantitative Myasthenia Gravis score, -14 (-19 to -9) for Myasthenia Gravis Composite score, and -9 (-15 to -3) for Myasthenia Gravis Quality of Life 15-revised score. INTERPRETATION: In this first study of an rCAR-T therapy in individuals with an autoimmune disease, Descartes-08 appeared to be safe and was well tolerated. Descartes-08 infusions were followed by clinically meaningful decreases on myasthenia gravis severity scales at up to 9 months of follow-up. rCAR-T therapy warrants further investigation as a potential new treatment approach for individuals with myasthenia gravis and other autoimmune diseases. FUNDING: Cartesian Therapeutics and National Institute of Neurological Disorders and Stroke of the National Institutes of Health.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Granit V, Benatar M, Kurtoglu M, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. Lancet Neurol. 2023. PMID: 37353278. doi:10.1016/S1474-4422(23)00194-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。